Loratadine

Global Loratadine Market to Reach US$347.5 Million by 2030

The global market for Loratadine estimated at US$306.3 Million in the year 2024, is expected to reach US$347.5 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$156.0 Million by the end of the analysis period. Growth in the Capsules segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.4 Million While China is Forecast to Grow at 4.0% CAGR

The Loratadine market in the U.S. is estimated at US$83.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$65.0 Million by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Loratadine Market – Key Trends & Drivers Summarized

What Is Loratadine and Why Is It Widely Used in Allergy Management?
Loratadine is a second-generation antihistamine commonly used to treat symptoms of allergic rhinitis (hay fever), urticaria (hives), and other skin or respiratory allergies. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms such as sneezing, runny nose, itchy eyes, and skin rashes. Unlike first-generation antihistamines, loratadine is non-sedating, making it highly favorable for daytime use, especially among working adults and children. It is available in various forms including tablets, syrups, and orally disintegrating tablets, and is marketed under numerous brand names globally, with Claritin being among the most recognized.

Its over-the-counter (OTC) availability in many countries has further boosted its popularity, allowing consumers to self-manage mild to moderate allergy symptoms without needing a prescription. Loratadine is also included in numerous combination therapies with decongestants or corticosteroids for enhanced symptom relief. The increasing prevalence of seasonal allergies, environmental pollution, and sensitivity to indoor allergens has maintained consistent global demand for loratadine, making it a staple in the antihistamine drug class within both retail pharmacy and healthcare provider channels.

What Market Trends and Innovations Are Shaping the Loratadine Landscape?
The loratadine market is evolving with the rising demand for user-friendly formulations, combination therapies, and generic alternatives. There has been a growing shift toward fast-dissolving tablets and liquid gels to improve convenience and onset of action, particularly for pediatric and geriatric populations. Pharmaceutical companies are also developing dual-action products that combine loratadine with pseudoephedrine (a decongestant) to treat both allergy and sinus symptoms in a single dose—catering to the needs of consumers with multiple upper respiratory complaints.

Additionally, the expiration of original patents has led to a surge in the production and availability of cost-effective generic versions, increasing affordability and accessibility in emerging markets. Consumer preferences for non-drowsy, long-lasting allergy relief have kept loratadine competitive despite the availability of newer antihistamines like fexofenadine or levocetirizine. E-commerce channels and telehealth platforms have further expanded the market’s reach, enabling easy purchase and digital prescription fulfillment. Moreover, ongoing R&D in drug delivery systems is expected to bring extended-release and intranasal loratadine formulations to market, diversifying its therapeutic utility and improving patient adherence.

What Factors Are Driving Growth in the Global Loratadine Market?
The growth in the global loratadine market is driven by several factors, including increasing incidence of allergic conditions, the expanding OTC pharmaceutical segment, and the growing awareness of non-sedating antihistamines. As urbanization, air pollution, and climate variability intensify, the prevalence of seasonal and perennial allergies is on the rise, leading more consumers to seek reliable, fast-acting symptom relief. Loratadine’s safety profile and long-established efficacy make it a go-to option for both self-medication and physician-prescribed regimens.

Another key growth driver is the rising demand for generic drugs, particularly in cost-sensitive healthcare markets across Asia-Pacific, Latin America, and parts of Africa. This is encouraging pharmaceutical companies to expand loratadine production and distribution through regional partnerships and regulatory approvals. Increased healthcare spending, higher awareness of allergy symptoms, and broader insurance coverage in developing economies are also boosting sales volume. Additionally, the inclusion of loratadine in national essential medicines lists and public health programs reinforces its importance in basic allergy treatment protocols, contributing to sustained and widespread global market growth.

SCOPE OF STUDY:

The report analyzes the Loratadine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Form (Tablets, Capsules, Syrups, Other Forms); Grade (USP Standard Grade, EP Standard Grade, Medicine Standard Grade, Other Grades); End-Use (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Apotex Inc.
• Bayer AG
• Cadila Pharmaceuticals
• Dr. Reddy`s Laboratories
• Glenmark Pharmaceuticals
• Hetero Drugs Limited
• Lupin Limited
• Merck & Co., Inc.
• Morepen Laboratories Ltd.
• Mylan N.V.
• Perrigo Company plc
• Pfizer Inc.
• Ranbaxy Laboratories Ltd.
• Schering-Plough (now part of Merck)
• Sun Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Wockhardt Ltd.
• Zydus Cadila

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.